Table 1.
Characteristics of patients in irAE and non-irAE groups
| All patients No. (%) |
irAE group No. (%) |
non-irAE group No. (%) |
P-value | |
|---|---|---|---|---|
| Total N | 65 | 14 | 51 | |
| Age | ||||
| < 65 | 28 (43.1) | 4 (28.6) | 24 (47.1) | 0.24 |
| ≥ 65 | 37 (56.9) | 10 (71.4) | 27 (52.9) | |
| Sex | ||||
| Female | 14 (21.5) | 6 (42.9) | 8 (15.7) | 0.06 |
| Male | 51 (78.5) | 8 (57.1) | 43 (84.3) | |
| ECOG PS | ||||
| 0 | 7 (10.8) | 4 (28.6) | 3 (5.9) | 0.03 |
| ≥ 1 | 58 (89.2) | 10 (71.4) | 48 (94.1) | |
| Number of metastatic sites | ||||
| < 2 | 16 (24.6) | 3 (21.4) | 13 (25.5) | 1.00 |
| ≥ 2 | 49 (75.4) | 11 (78.6) | 38 (74.5) | |
| ALP | ||||
| Low | 31 (47.7) | 7 (50.0) | 24 (47.1) | 1.00 |
| High | 34 (52.3) | 7 (50.0) | 27 (52.9) | |
| Histologic type | ||||
| Intestinal | 34 (52.3) | 9 (64.3) | 25 (49.0) | 0.37 |
| Diffuse | 31 (47.7) | 5 (35.7) | 26 (51.0) | |
| HER2 status | ||||
| Positive | 13 (20.0) | 11 (78.6) | 41 (80.4) | 1.00 |
| Negative | 52 (80.0) | 3 (21.4) | 10 (19.6) | |
| Disease status | ||||
| Stage IV | 32 (49.2) | 4 (28.6) | 28 (54.9) | 0.13 |
| Recurrence | 33 (50.8) | 10 (71.4) | 23 (45.1) | |
| NLR | ||||
| Low (< 4) | 37 (56.9) | 8 (57.1) | 29 (56.9) | 0.96 |
| High (≥4) | 28 (43.1) | 6 (42.9) | 22 (43.1) | |
| Baseline blood cell count median (range) | ||||
| WBC (/μL) | 3900 (2500–19,900) | 4900 (3700–14,300) | 6300 (2500–19,900) | 0.06 |
| Neutrophil (/μL) | 2570 (1310–18,710) | 3210 (2180–9880) | 4290 (1310–18,710) | 0.06 |
| Lymphocyte (/μL) | 965 (400–3230) | 1080 (650–2820) | 1080 (650–3230) | 0.67 |
| Eosinophil (/μL) | 91 (0–839) | 121 (18–684) | 91 (0–839) | 0.22 |
| NLR | 2.60 (1.00–31.2) | 2.92 (1.00–6.33) | 3.54 (1.16–31.2) | 0.21 |
ALP alkaline phosphatase, ECOG PS Eastern Cooperative Oncology Group Performance Status, irAE immune-related adverse event, NLR neutrophil-to-lymphocyte ratio, WBC white blood cell